Tin tức & Cập nhật

Treatment with obeticholic acid (OCA) improves clinical outcome in patients with precirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH), with a reduction in histological progression to cirrhosis seen in those receiving the 25-mg dose, as seen in the final results of the REGENERATE study.

Patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis treated with resmetirom achieve NASH resolution with no fibrosis worsening (NR) or ≥1-stage fibrosis improvement with no worsening of the NAS score (FI), according to the results of the ongoing MAESTRO-NASH study.

An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.

The addition of statins to standard adjuvant breast cancer treatment, particularly in combination with chemotherapy, appears to improve patient survival, suggests a study presented at ESMO Breast Cancer 2024.

In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.